GLP-1 Peptides: Approved Medicines and the Lookalikes
GLP-1 medicines cleared large trials and carry labelled uses. How to tell an approved product from a grey-market vial, and what FDA has said about the difference.
Start here
Plain English
GLP-1 medicines such as certain semaglutide and tirzepatide products are FDA-approved prescription drugs with large trials behind them for specific uses. They are not the same as research-chemical weight-loss peptides from unnamed vendors, and access runs through licensed care.
- Approved GLP-1 drugs are prescription medicines with known labels and risks.
- Unapproved “research” copies are a different legal and safety problem.
- We explain the landscape; only a clinician can decide if a drug is right for you.
GLP-1 peptides sit in the one peptide bucket that actually has modern blockbuster drugs - and a shadow market riding their demand.
What the term covers
| Meaning | Status | How to think about it |
|---|---|---|
| FDA-approved GLP-1 / related incretin drugs | Prescription medicines | Labelled indications, risks, monitoring |
| Compounded versions | Constrained pharmacy compounding rules | Not “anything goes”; quality varies |
| Unapproved / research-labelled products | Not approved for the marketed use | FDA has documented real harms |
This site’s three-bucket model puts true approved products in Prescription. Research chemicals like BPC-157 are a different category entirely. See what are peptides?.
The first row of that table is the only one with a regulator’s approval behind it, and it has one on both sides of the Pacific.
US legal status - FDA-approved · prescription only
Several GLP-1 and dual-incretin products are FDA-approved prescription medicines with labelled indications, and access runs through a licensed prescriber. Compounded and "research-labelled" copies are not those products and do not inherit their approval.
AU legal status - TGA-registered · prescription only
Semaglutide and tirzepatide are both Schedule 4 of the Poisons Standard - prescription only - and registered products containing them are on the ARTG. Prescription medicines cannot lawfully be advertised to the Australian public, so an Australian reader being sold one of these directly is being sold it by someone breaking that rule.
Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.
Why search volume exploded
Weight-loss demand pulled millions of people into peptide vocabulary. That same demand created:
- Legitimate telehealth and pharmacy pathways for approved drugs
- Compounded alternatives during shortages and after
- Unapproved products sold with dosing culture borrowed from forums
FDA’s public statements on unapproved GLP-1 drugs used for weight loss are required reading if you are comparing options. They discuss adverse event reports, dosing errors, and quality problems.
What we will not do here
- Recommend a brand, dose, or grey-market source
- Equate “peptide therapy” menus with approved GLP-1 care
- Pretend reconstitution calculators replace a prescriber
Arithmetic literacy (if you already use labelled products under clinical care): dosage calculator · how to reconstitute
How this differs from research peptides
| Approved GLP-1 class drugs | Typical research peptides | |
|---|---|---|
| Human trials | Extensive for labelled products | Often thin or absent |
| Manufacturing | Regulated drug supply chain | Research-chemical market |
| Legal status | Prescription | Not approved for human use |
| Sport / WADA | Check current list for your substance | Many research peptides banned |
Related
- Peptide therapy
- Peptide injections
- Peptide side effects
- Are peptides safe?
- Research peptides and the law
References
Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.
- 1.FDA - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (adverse events, dosing errors, counterfeits).- US Food and Drug Administrationregulatory
- 2.FDA - bulk drug substances used in compounding under section 503A.- US Food and Drug Administrationregulatory
- 3.21 U.S.C. §321 - drug definition under the FD&C Act.- Cornell Legal Information Institutestatute
- 4.Therapeutic Goods (Poisons Standard - June 2026) Instrument 2026, the current Poisons Standard (SUSMP). Semaglutide and tirzepatide are both Schedule 4 - prescription only - in Australia.- Federal Register of Legislation, Australian Governmentstatute
- 5.ARTG 315107 - OZEMPIC 1 mg semaglutide (rys) solution for injection pre-filled pen. Registered medicine, sponsor Novo Nordisk Pharmaceuticals Pty Ltd, ARTG date 28 August 2019.- Therapeutic Goods Administration, Australian Governmentdatabase
- 6.ARTG 407050 - MOUNJARO tirzepatide 5 mg/0.5 mL solution for injection vial. Registered medicine, sponsor Eli Lilly Australia Pty Ltd, ARTG date 10 July 2023.- Therapeutic Goods Administration, Australian Governmentdatabase
- 7.TGA - What can and cannot be advertised to the general public. Prescription-only medicines and substances cannot be advertised to the Australian public, and neither can unapproved therapeutic goods.- Therapeutic Goods Administration, Australian Governmentregulatory